As Omicron Takes Hold and Other New Variants Arise, COVID-19 Testing Remains the Universally Agreed Tool to Effect Transition From Pandemic to Endemic State

The COVID-19 pandemic has caused more than 448 million cases and 6 million deaths worldwide to date. Omicron is now the dominant SARS-CoV-2 variant, making up more than 90% of cases in countries reporting sequencing data. As the pandemic continues into its third year, continued testing is a strategic and necessary tool for transitioning to an endemic state of COVID-19. Here, we address three critical topics pertaining to the transition from pandemic to endemic: defining the endemic state for COVID-19, highlighting the role of SARS-CoV-2 testing as endemicity is approached, and recommending parameters for SARS-CoV-2 testing once endemicity is reached. We argue for an approach that capitalizes on the current public health momentum to increase capacity for PCR-based testing and whole genome sequencing to monitor emerging infectious diseases. Strategic development and utilization of testing, including viral panels in addition to vaccination, can keep SARS-CoV-2 in a manageable endemic state and build a framework of preparedness for the next pandemic.

[1]  M. Emamian,et al.  Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies , 2022, Current Microbiology.

[2]  Our world in data , 2022 .

[3]  R. Peeling,et al.  Diagnostics for COVID-19: moving from pandemic response to control , 2021, The Lancet.

[4]  C. del Rio,et al.  SARS-CoV-2 Testing Before International Airline Travel, December 2020 to May 2021 , 2021, Mayo Clinic Proceedings.

[5]  R. Neher,et al.  Novel SARS-CoV-2 variants: the pandemics within the pandemic , 2021, Clinical Microbiology and Infection.

[6]  Nicky Phillips,et al.  The coronavirus is here to stay — here’s what that means , 2021, Nature.

[7]  J. Tate,et al.  Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[8]  P. Serón,et al.  Recommendations for SARS-CoV-2/COVID-19 testing: a scoping review of current guidance , 2021, BMJ Open.

[9]  S. Fontana,et al.  Multiplex rt-Real Time PCR assays for diagnostic testing of SARS-CoV-2 and seasonal influenza viruses. A challenge of the phase 3 pandemic setting. , 2020, The Journal of infectious diseases.

[10]  Mary D. Fortune,et al.  Specificity and positive predictive value of SARS-CoV-2 nucleic acid amplification testing in a low-prevalence setting , 2020, Clinical Microbiology and Infection.

[11]  K. Jayatilleke Challenges in Implementing Surveillance Tools of High-Income Countries (HICs) in Low Middle Income Countries (LMICs) , 2020, Current Treatment Options in Infectious Diseases.

[12]  Savannah L. Bergquist,et al.  COVID-19 pandemic in the United States , 2020, Health Policy and Technology.